MMM

What Does the Market Think of 3M Company (MMM) Shares?

This afternoon we watched 3M Company drop -1.5% to a price of $103.98 per share. The large-cap Medical Instruments & Supplies company is now trading -8.47% below its average target price of $113.6. Analysts have set target prices ranging from $96.0 to $123.4 per share for 3M Company, and have given the stock an average rating of hold.

The stock has an average amount of shares sold short at 2.0%, and a short ratio of 3.19. The company's insiders own 0.12% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 67.4% of 3M Company's shares being owned by this investor type.

Institutions Invested in 3M Company

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 9% 48,716,196 $5,065,510,223
2023-06-30 Blackrock Inc. 7% 39,805,959 $4,139,023,750
2023-06-30 State Street Corporation 6% 33,311,747 $3,463,755,564
2023-06-30 Charles Schwab Investment Management, Inc. 2% 12,898,458 $1,341,181,706
2023-06-30 Geode Capital Management, LLC 2% 11,846,089 $1,231,756,373
2023-06-30 Morgan Stanley 2% 10,231,007 $1,063,820,142
2023-06-30 Flossbach von Storch AG 2% 9,580,844 $996,216,191
2023-06-30 State Farm Mutual Automobile Insurance Co 2% 9,557,100 $993,747,290
2023-06-30 Newport Trust Company, LLC 2% 8,520,186 $885,928,968
2023-06-30 Northern Trust Corporation 1% 6,846,439 $711,892,750

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on 3M Company.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS